Regenerative peptides for inferior alveolar nerve injury: a narrative review.
Regenerative peptides may offer potential for IAN repair, but current evidence is largely preclinical and lacks direct applicability to human cases. Further research is essential to establish their safety and efficacy.
Where it sits
this study against the rest of the cibinetide corpusSummary and findings
This narrative review assessed the mechanistic rationale and preclinical evidence for regenerative peptides in inferior alveolar nerve injury. It highlighted the potential of ARA-290 (cibinetide) among others, but noted a lack of direct evidence for efficacy in IAN injury. The review emphasizes the need for further research to establish safety and efficacy in relevant models.
Abstract
Inferior alveolar nerve (IAN) injury is a clinically important complication of oral and maxillofacial procedures that can lead to persistent neurosensory impairment, and effective regenerative interventions are presently scarce. This narrative review assessed the mechanistic rationale, preclinical evidence, translational limitations, and potential future relevance of regenerative peptides for IAN repair. Particular attention is given to BPC-157, thymosin <i>β</i>4 (T<i>β</i>4) and its related synthetic fragment TB-500, and ARA-290 (cibinetide), whose reported biological functions intersect with primary mechanisms implicated in peripheral nerve regeneration, such as cellular survival, Schwann cell activity, inflammatory modulation, angiogenesis, extracellular matrix remodeling, and axonal regeneration. Nevertheless, the available evidence is mainly sourced from pre-clinical and non-IAN systems, and direct evidence of efficacy in iatrogenic or traumatic IAN injury remains inadequate. BPC-157 and TB-500 remain investigational compounds with important safety, pharmacokinetic, and regulatory uncertainties, whereas evidence associated with TB-500 should be differentiated from that obtained with full-length T<i>β</i>4. Translation to IAN injury is further complicated by the lack of validated local delivery approaches, uncertain target-site pharmacokinetics, the anatomically restricted mandibular canal, and injury severity. Potential combination strategies involving traditional therapies, biomaterial-assisted delivery frameworks, and dental stem cell-mediated regenerative approaches are mechanistically plausible but remain hypothesis-generating rather than definitive synergistic interventions. Prospective research should prioritize IAN-relevant experimental systems, injury-severity classification, standardized outcome measures, target-site pharmacokinetics, and rigorously controlled clinical trials. Overall, regenerative peptides constitute a biologically plausible but currently investigational method for IAN repair, and their clinical application will rely on exhibiting reproducible efficacy and safety within indication-specific models and human trials.
Background
Inferior alveolar nerve (IAN) injury is a significant complication following oral and maxillofacial procedures, often leading to long-term neurosensory issues. Previous studies have indicated a need for effective regenerative interventions, yet options remain limited. This review aims to explore the potential of regenerative peptides, including Cibinetide, in promoting nerve repair, while addressing the existing gaps in evidence.
Methods
The review synthesizes existing literature on regenerative peptides, focusing on their mechanisms and preclinical findings related to nerve regeneration. It does not present original research data but rather discusses the implications of previously published studies. Specific details on sample size, dose, or duration are not provided.
Results
Not reported in abstract.
Interpretation
The review highlights that while regenerative peptides may have biological plausibility for nerve repair, the evidence primarily stems from non-IAN systems. The lack of robust clinical data and the challenges in translating findings to IAN injury limit the conclusions that can be drawn. The effect sizes and clinical significance of the peptides discussed remain uncertain, necessitating further investigation.
Key findings
- Not reported in abstract.
Limitations
- Review based on preclinical evidence.
- Lacks direct clinical data for IAN injury.
- Significant uncertainties regarding safety and efficacy.
- No original research data presented.